Biotin interference on immunoassay methods: Sporadic cases or hidden epidemic?

Clinical Chemistry and Laboratory Medicine

Volumn 55, Issue 6, 2017, Pages 777-779

  Clerico, Aldo ^a   Plebani, Mario ^b  

^a CNR   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; C PEPTIDE; FOLLITROPIN; HYDROCORTISONE; LIOTHYRONINE; LUTEINIZING HORMONE; PARATHYROID HORMONE; STREPTAVIDIN; THYROTROPIN; VITAMIN D;

DIAGNOSTIC ERROR; DRUG ADSORPTION; FREE THYROXINE INDEX; HORMONE BLOOD LEVEL; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; REVIEW; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

BIOTIN; HUMANS; IMMUNOASSAY;

EID: 85019075646     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2017-0070     Document Type: Review

References (17)

1. Tate J, Ward G. Interferences in immunoassay. Clin Rev Biochem 2004;25:105-20.
2. Plebani M. Errors in clinical laboratories or errors in laboratory medicine? Clin Chem Lab Med 2006;44:750-9.
3. Sturgeon C, Vijoen A. Analytical error and interference in immunoassay: minimizing risk. Ann Clin Biochem 2011;48:418-32.
4. Siest G, Dawkins SJ, Galteau MM. Drug effects on clinical laboratory tests. J Pharm Biomed Anal 1983;1:247-57.
5. Iervasi G, Clerico A, Bonini R, Manfredi C, Berti S, Ravani M, et al. Acute effects of amiodarone administration on thyroid function in patients with cardiac arrhythmia. J Clin Endocrinol Metab 1997;82:275-80.
6. Tarazi RC, Dustan HP, Frohlic ED. Long-term thiazide therapy in essential hypertension. Evidence for persistent alteration in plasma volume and renin activity. Circulation 1970;41:709-17.
7. Glassman AB. Hemostatic abnormalities associated with cancer and its therapy. Ann Clin Lab Sci 1997;27:391-5.
8. Dimeski G. Interference testing. Clin Biochem Rev 2008;29(suppl 1):S43-8.
9. Diamandis EP, Christopoulos TK. The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem 1991;37:625-36.
10. Rulander NJ, Cardamone D, Senior M, Snyder PJ, Master SR. Interference from anti-streptavidin antibody. Arch Pathol Lab Med 2013;137:1141-6.
11. Piketty M-L, Polak M, Flechtner I, Gonzales-Briceño L, Souberbielle J-C. False biochemical diagnosis of hyperthyroidism in streptavidin-biotin-based immunoassays: the problem of biotin intake and related interferences. Clin Chem Lab Med 2017;55:780-8.
12. Minkovsky A, Lee MN, Dowlatshahi M, Angell TE, Mahrokhian LS, Petrides AK, et al. High-dose biotin treatment for secondary progressive multiple sclerosis may interfere with thyroid assays. AACE Clin Case Rep 2016;2:e370-3.
13. Batista MC, Ferreira CE, Faulhaber AC, Hidal JT, Lottenberg SA, Mangueira CL. Biotin interference in immunoassays mimicking subclinical Graves' disease and hyperestrogenism: a case series. Clin Chem Lab Med 2017;55:e99-103.
14. Piketty M-L, Prie D, Sedel F, Bernard D, Hercend C, Chanson P, et al. High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference. Clin Chem Lab Med 2017;55:817-25.
15. Tabarki B, Al-Shafi S, Al-Shahwan S, Azmat Z, Al-Hashem A, Al-Adwani N, et al. Biotin-responsive basal ganglia disease revisited: clinical, radiologic, and genetic findings. Neurology 2013;80:261-7.
16. Sedel F, Papeix C, Bellanger A, Touitou V, Lebrun-Frenay C, Galanaud D, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord 2015;4:159-69.
17. Lam L, Kyle CV. A simple method to detect biotin interference on immunoassays. Clin Chem Lab Med 2017;55:e104-6.